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Psoriasis is a glowing example of collabora-
tion between clinicians and scientists in an effort 
to find safe and effective therapies for this debili-
tating genetic disorder of the skin, joints, and 
immune system. In some instances, fortuitous 
clinical observations drove the laboratory work 
that explained the pathogenesis of this disorder; 
at other times, therapies were based on find-
ings in the lab. The result has been a dramatic 
improvement in our understanding of the patho-
genesis of this disorder and in our ability to treat 
psoriatic patients.
Psoriasis was first thought to be a prima-
ry disorder of the keratinocyte. In the 1960s, 
Weinstein, van Scott, and Frost demonstrated 
abnormal proliferation of keratinocytes in pso-
riasis (Weinstein and Van Scott, 1965; Weinstein 
and Frost, 1968). The turnover time of psoriatic 
epidermis was shown to be markedly faster than 
that of normal epidermis. Concurrently, van 
Scott, Auerbach, and Weinstein showed that 
methotrexate was effective in psoriasis, presum-
ably by targeting those rapidly dividing epider-
mal cells (Van Scott et al., 1964). Shortly there-
after, Parrish, Fitzpatrick, and colleagues intro-
duced the combination of psoralen and UVA 
(PUVA) (Melski et al., 1977). PUVA was thought 
to cross-link DNA strands, and the primary effect 
was again considered an inhibition of the pro-
liferation of keratinocytes (Lerche et al., 1979). 
It wasn’t until years later that we appreciated 
the impact of methotrexate and of PUVA on the 
immune system. 
Involvement of the immune system in the 
pathogenesis of psoriasis was first appreciat-
ed as a result of the fortuitous observation that 
transplant patients who had psoriasis and were 
treated with cyclosporine exhibited remarkable 
improvement of their skin disease (Picascia et al., 
1988). Griffiths and Voorhees were among the 
first to point out that cyclosporine’s beneficial 
effect on psoriasis was attributable to the drug’s 
impact on T lymphocytes. With co-workers, they 
showed that cyclosporine reduces numerous 
immune cells including T lymphocytes, mono-
cytes, macrophages, and antigen-presenting 
cells (Griffiths and Voorhees, 1990; Gupta et al., 
1989). Working with an illustrious group of sci-
entists, they demonstrated many changes in the 
immune system from cyclosporine therapy and 
theorized that upon activation of T cells, lesional 
T cells released lymphokines that promote kera-
tinocyte proliferation (Baadsgaard et al., 1990).
Independently, Gottlieb and Nickoloff and 
Griffiths espoused the same point of view, that 
is, that the T lymphocyte played a critical role in 
the pathogenesis of psoriasis and was an impor-
tant target for psoriasis therapies (Gottlieb, 1988; 
Nickoloff and Griffiths, 1990). The role of the 
lymphocyte was convincingly confirmed when a 
group led by James Krueger successfully treated 
psoriasis using a lymphocyte-selective fusion 
protein consisting of interleukin-2 and fragments 
of diphtheria toxin (Gottlieb et al., 1995). The 
latter compound selectively blocks activated 
lymphocytes but has no effect on keratinocytes. 
Eight of 10 patients treated with two doses of this 
fusion protein had moderate to marked improve-
ment, confirming the role of the lymphocyte. 
With attention focused on the T cell, our 
knowledge about the pathogenesis of psoria-
sis was now poised to move forward quickly. It 
was known that activation of T cells requires not 
only antigen presentation to the T cells, but also 
costimulation with a number of possible sig-
nals. B7 molecules on the surface antigen-pre-
senting cells were shown to provide an impor-
tant costimulatory signal to their T cell–associ-
ated ligands, CD28 and CD152, also known as 
cytotoxic T lymphocyte–associated antigen-4 
(CTLA-4) (Abrams et al., 1999). CTLA-4 Ig, now 
known as abatacept, is a fusion protein consist-
ing of the Fc portion of human IgG1 fused with 
the extracellular domain of CTLA-4. By binding 
to B7 molecules, abatacept prevents the second 
costimulatory signal, thereby blocking T-cell 
activation and resulting in improvement in pso-
riasis (Abrams et al., 1999). Abatacept, approved 
for the treatment of rheumatoid arthritis, is still 
Biologics for Psoriasis:  A Translational 
Research Success Story
Journal of Investigative Dermatology (2015) 135, 1205–1462. 
doi:10.1038/jid.2014.549
editorial
1206 Journal of Investigative Dermatology (2015), Volume 135 
being studied for psoriasis and psoriatic arthritis. 
Soon the concept of a cytokine network in genetically 
predisposed individuals leading to abnormal keratinocyte 
proliferation in reaction to infectious or traumatic skin expo-
sures began to emerge. The role of the Th1 cytokine, IFN-γ, 
was recognized early (Huang et al., 2001). In this cytokine 
network, activation of lymphocytes and T-cell trafficking 
were thought to play important roles. Two biologics that were 
constructed to block T-cell activation, alefacept and efali-
zumab, were briefly on the market for the treatment of pso-
riasis. Efalizumab also interfered with T-cell trafficking into 
inflamed skin (Krueger et al., 2002; Lebwohl et al, 2003).
The role of TNF-α was not appreciated until clinical effica-
cy had been anecdotally demonstrated (Chamian & Krueger, 
2004). After clinical observations that TNF-α antagonists 
were effective, it was shown that these drugs result in rapid 
reduction of IL-1 and IL-8 followed by reductions in inflam-
matory gene expression including IFN-γ, Stat-1, and gran-
zyme B (Gottlieb et al., 2005). The reduction in T-cell acti-
vation and decreased production of cytokines, chemokines, 
and growth factors by lymphocytes, neutrophils, dendritic 
cells, and keratinocytes stopped the vicious cycle of immune 
activation leading to keratinocyte proliferation and inflam-
mation. 
In the evolving cytokine network leading to psoriasis, 
Nestle and Conrad pointed out as early as 2004 that p40 was 
thought to play an important role in psoriasis (Nestle and 
Conrad, 2004). This led to the development of two antibod-
ies targeting p40, ustekinumab and briakinumab (Lebwohl 
et al., 2012; Reich et al., 2011). Both biologic agents, which 
target the p40 components of IL-12 and IL-23, were dramati-
cally effective but because of a small increase in myocardial 
infarctions in pivotal trials, briakinumab’s approval was not 
pursued. 
As our understanding of the cytokine network response to 
psoriasis evolved, Nickoloff, Nestle, and colleagues pointed 
out the importance of the IL-23/IL-17 axis (Tonel et al., 2010; 
Di Cisare et al., 2009). We now know that IL-23 upregulates 
Th-17 cells to create more IL-17. At least three antibodies 
targeting IL-17 or its receptor have been studied clinically. 
The first of these, the recently approved secukinumab, tar-
gets IL-17A and has proven to be dramatically effective in 
the treatment of psoriasis (Langley et al., 2014). Ixekizumab, 
another antibody to IL-17A, is equally effective, as is bro-
dalumab, an antibody to the IL-17 receptor (Leonardi et al., 
2012; Papp et al., 2012).
In conclusion, for the past five decades, advances in our 
understanding and treatment of psoriasis have resulted from 
a close collaboration between scientists and clinicians, mak-
ing psoriasis a model of a disease where basic laboratory 
scientists and clinicians benefit from interacting with one 
another. Advances in the laboratory have translated into new 
therapies that are more targeted, profoundly effective, and 
safer than older treatments. The next frontier in psoriasis is 
likely to involve pharmacogenomics or, in the distant future, 
even gene therapy. We already have a head start thanks to 
the extensive work identifying psoriasis-associated genes 
(Gudjonsson et al., 2010; Bowcock et al., 2001; Cargill et al., 
2007).
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Editor's Note
Since beginning my term as JID Editor in 2012, the 
importance of unity among the many stakeholders in 
dermatologic research has become increasingly obvi-
ous. The interaction and mutual support of two of these 
communities—practicing dermatologists and investiga-
tors—are especially critical to the future of our specialty. 
It therefore gives me particular pleasure to see featured 
in this issue an editorial by the president of the American 
Academy of Dermatology, the elected representative 
and spokesperson for more than 10,000 dermatologists 
as well as one of the foremost clinical investigators and 
thought leaders in translational research. Dr. Lebwohl 
beautifully summarizes the advances in basic under-
standing of the disease psoriasis that have led to progres-
sively targeted and effective therapies within a remark-
ably short time.
Barbara A. Gilchrest
Editor
